Wrong confirmation ID
  • Email
  • Favorite
  • Download
  • Embed
  • Private Content

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Pharma Search Engine Marketing - Bounce Rates: Did the FDA Warning Letters on Paid Search Have An Impact? Ian Orekondy

by SearchandSocialMedia.com on Jan 01, 2010

  • 1,868 views

Pharma Search Engine Marketing: ...

Pharma Search Engine Marketing:
In April of 2009, the FDA's DDMAC issued 48 Warning Letters to 14 pharmaceutical companies regarding their use of paid search (SEM) advertising.

The three issues that were cited as reasons for identifying certain pharma paid search text ads as non-compliant were:
1) Omission of Risk Information (the End of the “One-Click” rule)
2) Failure to Use Required Established Name
3) Inadequate Communication of Indication

Almost all major pharma SEM advertisers paused their campaigns and revamped their text ads to comply with the FDA guidance, resulting in two main types of ads:
1) Branded Reminder Ads
2) Unbranded Claim Ads

How Did The FDA Warning Letters And Pharma Advertisers' Shifting Campaign Strategies Impact Website Bounce Rates?

Accessibility

Categories

Tags

pharma bounce rates pharma benchmarks pharma web metrics pharma seo pharma sem

More...

Upload Details

Uploaded via SlideShare as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate. If needed, use the feedback form to let us know more details.

Cancel

1 Embed 9

http://www.slideshare.net 9

Statistics

Favorites
0
Downloads
35
Comments
1
Embed Views
9
Views on SlideShare
1,859
Total Views
1,868

11 of 1 previous next

Post Comment
Edit your comment Cancel

Pharma Search Engine Marketing - Bounce Rates: Did the FDA Warning Letters on Paid Search Have An Impact? Ian Orekondy — Presentation Transcript